[
    [
        {
            "time": "",
            "original_text": "财信证券维持大参林推荐评级：新冠疫情影响+费用增加，拖累2021Q2业绩表现，目标价67.60-76.05元 盈利能力下降",
            "features": {
                "keywords": [
                    "大参林",
                    "新冠疫情影响",
                    "费用增加",
                    "2021Q2业绩表现",
                    "盈利能力下降"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "财信证券维持大参林推荐评级：新冠疫情影响+费用增加，拖累2021Q2业绩表现，目标价67.60-76.05元 盈利能力下降",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 3,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        }
    ]
]